News Release: July 22, 2025
Medical-grade Cobalt-60 Price Trend in Past Five Years and Factors Impacting Price Movements (2019–2024)
Over the past five years, the Medical-grade Cobalt-60 price trend and production News has witnessed significant fluctuations due to evolving regulatory, geopolitical, and market-specific challenges. In 2019, the average Medical-grade Cobalt-60 price stood around $22,500/MT, supported by a stable supply chain from Canada and Russia. The demand for radiation therapy tools remained steady, with large-scale procurement by hospitals and nuclear medicine research centers.
However, by 2020, the Medical-grade Cobalt-60 price rose to approximately $24,200/MT due to the COVID-19 pandemic disrupting mining and isotope production facilities. Lockdowns affected operations at major production sites in North America and Europe, creating short-term scarcity and leading to higher Medical-grade Cobalt-60 sales volume across emergency health projects. The constrained logistics further inflated transportation costs, adding to the overall product pricing.
In 2021, global supply chains slowly recovered, and Medical-grade Cobalt-60 price trend started stabilizing. The average price was estimated at $23,400/MT. A major contributor to price moderation was the restarting of cobalt irradiation services in Asia-Pacific countries. However, at the same time, heightened geopolitical risks, particularly trade tensions involving nuclear materials, kept market uncertainty high.
The year 2022 marked a renewed demand spike with the global resumption of elective surgeries and expansion of oncology treatment infrastructure. Prices surged to nearly $26,300/MT. The increase in production from Russian and Chinese sources somewhat cushioned the pricing pressure, but compliance with international safety and export protocols raised operational costs.
2023 observed a marginal drop, with prices sliding to $25,700/MT due to improved inventory management practices and increased Medical-grade Cobalt-60 production capacities in India and South Korea. Still, elevated raw material prices, energy costs, and environmental regulations continued to challenge the cost structure.
By early 2024, Medical-grade Cobalt-60 price reached $27,100/MT, reflecting growing demand from advanced nuclear medicine procedures and research in developing economies. Innovation in cobalt capsule packaging and longer half-life variants also contributed to higher production costs, indirectly affecting the price.
Among key factors driving price changes include:
- Disruptions in cobalt mining supply, particularly from geopolitical hotspots.
- Regulatory delays in transport and isotope certification.
- Technological enhancements in sterilization and therapy delivery.
- Rising R&D investments in radiopharmaceutical applications.
- Import-export tariffs and safety protocol changes across regions.
While the Medical-grade Cobalt-60 price trend remains moderately volatile, the long-term outlook suggests a gradual upward momentum due to rising therapeutic demand.
Medical-grade Cobalt-60 Price Trend Quarterly Update in $/MT (Estimated 2024–2025)
Q1 2024 – $27,100/MT
Q2 2024 – $27,450/MT
Q3 2024 – $27,800/MT
Q4 2024 – $28,100/MT
Q1 2025 – $28,700/MT
Q2 2025 – $28,950/MT
Q3 2025 – $29,300/MT
Q4 2025 – $29,600/MT
The Medical-grade Cobalt-60 price news in 2025 reflects a steady increase across quarters due to strong demand from healthcare and medical research industries. The slight inflation in quarterly rates is attributed to advanced production techniques, logistical expenses, and international trade policies surrounding radioactive isotopes.
Global Medical-grade Cobalt-60 Import-Export Business Overview (2025 Outlook)
The global Medical-grade Cobalt-60 import-export business landscape continues to evolve amid stringent nuclear material handling regulations and growing international collaboration in radiotherapy technology. In 2025, key market participants include Canada, China, Russia, the United States, France, India, and South Korea, each playing pivotal roles in either production or reprocessing.
Canada remains the primary exporter of Medical-grade Cobalt-60, utilizing its nuclear reactors at Bruce Power and Nordion facilities. Exports from Canada have steadily grown since 2023, supported by bilateral trade agreements with the U.S., Germany, and Japan. With new sterilization contracts signed in Q2 2025, Canada’s Medical-grade Cobalt-60 sales volume is projected to surpass 600 MT this year alone.
Russia’s exports are largely directed toward Eastern Europe, Middle East, and Southeast Asia. While the nation faced occasional sanctions impacting isotope shipments, strategic partnerships with Chinese and Turkish institutions in 2025 have revitalized its export potential. Russia is expected to cross 400 MT in export volume this year, particularly focusing on high-energy radiation therapy applications.
China, on the other hand, is gradually transitioning from a net importer to a balanced producer and exporter of Medical-grade Cobalt-60. The development of domestic production hubs in Guangdong and Sichuan has contributed to localized supply, reducing reliance on foreign imports. In 2025, China’s exports are targeted at ASEAN and African regions, aligned with its health technology diplomacy.
The United States primarily imports Medical-grade Cobalt-60 from Canada and occasionally Europe. However, with government funding in place, two large isotope production facilities are scheduled to commence operations in Q3 2025 in Tennessee and Washington. These will initially reduce import volumes by nearly 20% while stimulating domestic Medical-grade Cobalt-60 production.
France, Germany, and the Netherlands import Medical-grade Cobalt-60 mostly for their radiation therapy facilities and research institutes. These countries are also actively exploring regional cobalt isotope generation systems under the EU’s nuclear innovation programs. Imports are expected to grow modestly in 2025, driven by increasing cancer therapy cases and cross-border diagnostic services.
India has rapidly increased its production and is now one of the emerging suppliers in South Asia and the Gulf region. The BARC (Bhabha Atomic Research Centre) is scaling up output capacity in 2025, and a new public-private partnership model with health technology firms is further enhancing export capabilities. India’s Medical-grade Cobalt-60 sales volume could reach 150 MT by end of year.
South Korea continues to import the bulk of its Medical-grade Cobalt-60 for use in sterilization and hospital cancer units. However, its growing collaboration with U.S. and Canadian firms for joint isotope generation may lead to export readiness by 2026. In 2025, South Korea remains a key importer in the Asia-Pacific region, reflecting stable Medical-grade Cobalt-60 price trend amidst domestic health expansion.
Africa and Latin America are increasingly relying on imports from Europe and Asia. Brazil, South Africa, and Egypt have signed new agreements with Canadian and Chinese suppliers for 2025–2027 delivery cycles. These markets are still in their infancy but present significant demand potential over the next five years.
Major trends shaping the global Medical-grade Cobalt-60 import-export market in 2025 include:
- Regionalization of isotope supply chains to reduce cross-border risks.
- Increasing involvement of private health firms in isotope sourcing.
- Technological convergence in cobalt-60 packaging and dosage accuracy.
- Accelerated licensing processes in fast-growing economies.
- Stable Medical-grade Cobalt-60 price news across mature markets.
The expected global trade volume for Medical-grade Cobalt-60 in 2025 may surpass 2,000 MT, marking a 6% increase over 2024. Emerging players such as India and China are closing the gap with legacy suppliers, while price trends remain favorable for expanding medical-grade radiotherapy and sterilization services.
For more in-depth analysis and a detailed report with pricing, production statistics, sales breakdown, and global trade flows, please visit the official report page and request sample here: https://datavagyanik.com/reports/medical-grade-cobalt-60-market-size-production-sales-average-product-price-market-share-import-vs-export/
Medical-grade Cobalt-60 Production Trends by Geography (2025)
The production of Medical-grade Cobalt-60 in 2025 is shaped by the strategic capabilities of nuclear infrastructure, government policy on radioactive isotope management, and demand from medical and research institutions. The global Medical-grade Cobalt-60 production is witnessing steady growth, with major contributions from North America, Europe, Asia-Pacific, and select emerging economies.
North America
Canada remains the leading global producer of Medical-grade Cobalt-60, largely due to its advanced nuclear facilities at Bruce Power and Nordion. These reactors are specifically optimized for cobalt-60 irradiation, making the country a dominant force in the isotope supply chain. In 2025, Canada has expanded its reactor output to meet growing international demand, supported by long-term contracts with U.S., Japanese, and European clients.
The United States, although historically reliant on imports, has invested significantly in domestic isotope production. New isotope processing units at Oak Ridge and other nuclear research labs are scheduled to reach commercial capacity in 2025. These facilities aim to reduce the country’s dependency on imports and bolster Medical-grade Cobalt-60 production through public-private partnerships.
Europe
European production is concentrated in countries like Russia and France. Russia operates large-scale nuclear reactors capable of producing cobalt-60 for medical use, and the government has intensified efforts to enhance isotopic capabilities despite international trade constraints. In 2025, Russia is ramping up reactor utilization to increase output and cater to regional demands across Eurasia and the Middle East.
France maintains smaller but highly efficient production facilities. The CEA (Atomic Energy Commission) oversees isotope production through controlled nuclear environments, primarily to serve national healthcare systems and select European export markets.
Germany and the Netherlands, although not major producers, are actively participating in research and development projects aimed at localized Medical-grade Cobalt-60 production through collaboration with private industry.
Asia-Pacific
China is becoming a significant player in Medical-grade Cobalt-60 production. With rapid advancements in nuclear medicine infrastructure, Chinese reactors in Guangdong, Sichuan, and Heilongjiang provinces have begun full-scale isotope generation. In 2025, China’s output is expected to double as it supplies domestic hospitals and exports to Southeast Asia and Africa.
India is emerging as a regional hub for cobalt-60 isotope production. Facilities under the Bhabha Atomic Research Centre (BARC) have expanded capabilities to supply both domestic and international markets. Government support and joint ventures with private diagnostics firms are driving India’s push to become a consistent exporter in South Asia and the Gulf region.
South Korea maintains moderate production levels but relies more on imports for large-scale demand. However, research initiatives with U.S. companies may result in increased local output by 2026.
Latin America and Africa
Latin American countries, especially Brazil and Argentina, are exploring domestic production of Medical-grade Cobalt-60. Brazil has initiated trials at nuclear facilities in São Paulo and Rio de Janeiro, although large-scale output is not expected until 2026.
In Africa, South Africa leads with the most developed nuclear infrastructure. The Pelindaba facility is exploring pilot-level isotope generation for medical purposes. However, current production volumes are low, and imports from Asia and Europe continue to dominate.
Middle East
The Middle East remains a minor producer of Medical-grade Cobalt-60 but has seen strategic initiatives in 2025. Countries like UAE and Saudi Arabia are investing in small-scale isotope generators under national health initiatives. These developments may transition into full-scale production by 2027.
In conclusion, the Medical-grade Cobalt-60 production map is transitioning from a few dominant suppliers to a wider, decentralized global base. While Canada, Russia, and China remain the top producers, emerging markets like India and Brazil are on a strong upward trajectory. The geographical diversification in 2025 supports both global supply chain stability and pricing predictability.
Medical-grade Cobalt-60 Market Segmentation
Segments:
- By Application
- By End User
- By Form
- By Distribution Channel
- By Geography
1. By Application
- Cancer Radiotherapy
- Sterilization of Medical Equipment
- Research and Development
- Industrial Radiography
The most prominent application of Medical-grade Cobalt-60 is cancer radiotherapy. Hospitals and oncology centers increasingly rely on cobalt-60-based radiation machines for treating tumors, especially in developing regions where advanced linear accelerators are less accessible. In 2025, demand for this segment continues to grow due to rising cancer prevalence and government-supported treatment programs.
Sterilization of medical equipment is another key segment, especially post-COVID, where infection control remains a high priority. Cobalt-60 is used in gamma irradiation chambers to sterilize syringes, surgical tools, and pharmaceuticals, making it essential in mass production healthcare ecosystems.
Research and development account for a niche but high-value segment. Medical research institutes use small cobalt-60 doses for experimental radiotherapy, isotopic tracing, and biological testing. This segment is expected to grow with new clinical trials in radiopharmaceuticals.
Industrial radiography, while less emphasized in the medical-grade category, occasionally overlaps in application due to shared technologies and licensing frameworks.
2. By End User
- Hospitals and Clinics
- Diagnostic and Research Laboratories
- Pharmaceutical Companies
- Contract Sterilization Facilities
Hospitals and clinics dominate the Medical-grade Cobalt-60 sales volume, particularly due to widespread use in cancer treatment units. In 2025, emerging economies are setting up cobalt-60 units due to their lower capital cost and effectiveness in high-throughput environments.
Diagnostic and research laboratories are growing steadily as personalized medicine gains traction. These users require isotopes for biomarker tracking and precision testing, driving specialty cobalt-60 demand.
Pharmaceutical companies increasingly utilize cobalt-60 in drug packaging sterilization, particularly in injectable biologics. Regulatory changes in 2024 have mandated improved sterility standards, increasing the share of this segment.
Contract sterilization facilities are third-party operators that service hospitals and pharma firms. They represent a large segment in developed nations, where outsourcing of sterilization processes is common.
3. By Form
- Pellet
- Rod
- Capsule
Pellet form remains the most used due to its compatibility with radiation equipment and ease of replacement. Capsules, which are sealed and safer to handle, are becoming more popular in newer machines. Rod form is less common but used in select gamma chambers.
4. By Distribution Channel
- Direct Sales
- Third-party Distributors
- Government Procurement
Direct sales dominate high-value hospital and government contracts. Third-party distributors handle logistics for mid-sized clinics and labs. Government procurement plays a critical role in developing countries where public tenders determine supply chains.
5. By Geography
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East & Africa
North America leads the market in both demand and production. Europe remains steady with niche high-tech demand, while Asia-Pacific is the fastest growing, led by China and India. Latin America and Africa are emerging markets with strong import dependency and growing infrastructure.
Leading Segment Analysis (2025)
The cancer radiotherapy segment is the highest revenue-generating application in 2025. Hospitals and clinics remain the largest end users, accounting for over 60% of Medical-grade Cobalt-60 sales volume globally. Pellet form remains the top-selling format, while direct sales through government contracts and hospital partnerships are the preferred distribution channels. Asia-Pacific stands out as the fastest-growing regional market, driven by healthcare investments and expanding diagnostic infrastructure.